FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943253226> ?p ?o ?g. }

• W2943253226 endingPage "673" @default.
• W2943253226 startingPage "673" @default.
• W2943253226 abstract "The prognosis of advanced melanoma has been greatly improved by new therapeutic agents and clinicians rely on dynamic signals to drive their therapeutic choices. Although the kinetics of metastatic disease seem to be correlated with survival, progression of the localized disease is not predictable.To assess whether progression of metastatic disease is associated with the time to the first distant recurrence of melanoma.This study was conducted from March 1, 2013, to September 1, 2017, among 638 adults with unresectable stage III or IV melanoma within the French multicentric prospective cohort MelBase. Patients treated with first-line immunotherapies, targeted therapies, or chemotherapy were included. Patients with unknown primary or de novo metastatic melanoma were not included. Data were analyzed from March 1, 2013, to December 1, 2017.The date of primary excision and time to first distant recurrence, progression-free survival, and overall survival were collected. Cox proportional hazards regression models were planned to assess the association between time to first distant recurrence and progression-free survival or overall survival, which was evaluated in terms of hazard ratio (HR). Time to recurrence was analyzed both as a continuous and categorical variable (<12 months, 12-24 months, and >24 months).A total of 638 patients (272 women and 366 men; median age, 64 years [interquartile range, 52-73 years]) were included in the study. The median time from primary excision to first distant recurrence was 25 months (interquartile range, 12-55 months). There was no evidence of association of the time to recurrence with progression-free survival, both when analyzed as a continuous variable (HR, 0.99; 95% CI, 0.99-1.01) or after categorization (12-24 months: HR, 0.75; 95% CI, 0.56-1.02; >24 months: HR, 0.62; 95% CI; 0.47-1.01). There was no evidence of association of the time to recurrence with overall survival, both when analyzed as a continuous variable (HR, 0.99; 95% CI, 0.98-1.02) or after categorization (12-24 months: HR, 0.76; 95% CI, 0.54-1.07; >24 months: HR, 0.61; 95% CI, 0.54-1.03). Those results remained nonsignificant after stratification by treatment.In the MelBase cohort, time to recurrence of metastatic melanoma appears not to be associated with progression-free survival or overall survival." @default.
• W2943253226 created "2019-05-09" @default.
• W2943253226 creator A5000446801 @default.
• W2943253226 creator A5002644565 @default.
• W2943253226 creator A5006200908 @default.
• W2943253226 creator A5007002871 @default.
• W2943253226 creator A5025478490 @default.
• W2943253226 creator A5029900243 @default.
• W2943253226 creator A5031791085 @default.
• W2943253226 creator A5034014576 @default.
• W2943253226 creator A5034402801 @default.
• W2943253226 creator A5034787940 @default.
• W2943253226 creator A5042125003 @default.
• W2943253226 creator A5042939436 @default.
• W2943253226 creator A5044024585 @default.
• W2943253226 creator A5044232799 @default.
• W2943253226 creator A5048685099 @default.
• W2943253226 creator A5055627811 @default.
• W2943253226 creator A5056909687 @default.
• W2943253226 creator A5058938160 @default.
• W2943253226 creator A5060779399 @default.
• W2943253226 creator A5064052929 @default.
• W2943253226 creator A5065819179 @default.
• W2943253226 creator A5066493529 @default.
• W2943253226 creator A5069323036 @default.
• W2943253226 creator A5077421764 @default.
• W2943253226 date "2019-06-01" @default.
• W2943253226 modified "2023-10-17" @default.
• W2943253226 title "Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival" @default.
• W2943253226 cites W1919811975 @default.
• W2943253226 cites W2005612119 @default.
• W2943253226 cites W2006986876 @default.
• W2943253226 cites W2071760604 @default.
• W2943253226 cites W2088035579 @default.
• W2943253226 cites W2127858747 @default.
• W2943253226 cites W2156405206 @default.
• W2943253226 cites W2169131681 @default.
• W2943253226 cites W2189916683 @default.
• W2943253226 cites W2336736728 @default.
• W2943253226 cites W2412669122 @default.
• W2943253226 cites W2800104500 @default.
• W2943253226 cites W4237647377 @default.
• W2943253226 doi "https://doi.org/10.1001/jamadermatol.2019.0425" @default.
• W2943253226 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6495357" @default.
• W2943253226 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31042256" @default.
• W2943253226 hasPublicationYear "2019" @default.
• W2943253226 type Work @default.
• W2943253226 sameAs 2943253226 @default.
• W2943253226 citedByCount "7" @default.
• W2943253226 countsByYear W29432532262019 @default.
• W2943253226 countsByYear W29432532262020 @default.
• W2943253226 countsByYear W29432532262021 @default.
• W2943253226 countsByYear W29432532262022 @default.
• W2943253226 countsByYear W29432532262023 @default.
• W2943253226 crossrefType "journal-article" @default.
• W2943253226 hasAuthorship W2943253226A5000446801 @default.
• W2943253226 hasAuthorship W2943253226A5002644565 @default.
• W2943253226 hasAuthorship W2943253226A5006200908 @default.
• W2943253226 hasAuthorship W2943253226A5007002871 @default.
• W2943253226 hasAuthorship W2943253226A5025478490 @default.
• W2943253226 hasAuthorship W2943253226A5029900243 @default.
• W2943253226 hasAuthorship W2943253226A5031791085 @default.
• W2943253226 hasAuthorship W2943253226A5034014576 @default.
• W2943253226 hasAuthorship W2943253226A5034402801 @default.
• W2943253226 hasAuthorship W2943253226A5034787940 @default.
• W2943253226 hasAuthorship W2943253226A5042125003 @default.
• W2943253226 hasAuthorship W2943253226A5042939436 @default.
• W2943253226 hasAuthorship W2943253226A5044024585 @default.
• W2943253226 hasAuthorship W2943253226A5044232799 @default.
• W2943253226 hasAuthorship W2943253226A5048685099 @default.
• W2943253226 hasAuthorship W2943253226A5055627811 @default.
• W2943253226 hasAuthorship W2943253226A5056909687 @default.
• W2943253226 hasAuthorship W2943253226A5058938160 @default.
• W2943253226 hasAuthorship W2943253226A5060779399 @default.
• W2943253226 hasAuthorship W2943253226A5064052929 @default.
• W2943253226 hasAuthorship W2943253226A5065819179 @default.
• W2943253226 hasAuthorship W2943253226A5066493529 @default.
• W2943253226 hasAuthorship W2943253226A5069323036 @default.
• W2943253226 hasAuthorship W2943253226A5077421764 @default.
• W2943253226 hasBestOaLocation W29432532261 @default.
• W2943253226 hasConcept C10515644 @default.
• W2943253226 hasConcept C119060515 @default.
• W2943253226 hasConcept C126322002 @default.
• W2943253226 hasConcept C141071460 @default.
• W2943253226 hasConcept C143998085 @default.
• W2943253226 hasConcept C207103383 @default.
• W2943253226 hasConcept C2776694085 @default.
• W2943253226 hasConcept C2777658100 @default.
• W2943253226 hasConcept C2779134260 @default.
• W2943253226 hasConcept C2780739268 @default.
• W2943253226 hasConcept C44249647 @default.
• W2943253226 hasConcept C502942594 @default.
• W2943253226 hasConcept C50382708 @default.
• W2943253226 hasConcept C71924100 @default.
• W2943253226 hasConcept C72563966 @default.
• W2943253226 hasConceptScore W2943253226C10515644 @default.
• W2943253226 hasConceptScore W2943253226C119060515 @default.
• W2943253226 hasConceptScore W2943253226C126322002 @default.

• next